Orphan receptor GPR50 attenuates inflammation and insulin signaling in 3T3-L1 preadipocytes

Zhenyu Yao1, Jun Meng2,3, Jing Long1

  • 1Centre for Translational Medicine Research & Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

FEBS Open Bio
|November 5, 2022
PubMed

Insights

G protein-coupled receptor 50 (GPR50) may reduce inflammation and improve insulin resistance in type 2 diabetes. GPR50 deficiency exacerbates inflammation and disrupts insulin signaling pathways in adipocytes.

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Cell Biology

Background:

  • Type 2 diabetes involves insulin resistance and inflammation.
  • G protein-coupled receptors (GPCRs) regulate metabolic processes.
  • GPR50, a GPCR, is structurally similar to melatonin receptors.

Purpose of the Study:

  • To investigate the role of GPR50 in inflammation and insulin resistance.
  • To explore GPR50's effects in 3T3-L1 preadipocytes.

Main Methods:

  • Examined GPR50 expression in obese T2DM mice adipose tissue.
  • Assessed GPR50 deficiency effects on 3T3-L1 cell inflammation.
  • Analyzed AKT, insulin receptor substrate (IRS) 1, and PPAR-γ expression in GPR50 knockout cells.

Main Results:

  • GPR50 expression increased in obese T2DM mice adipose tissue.
  • GPR50 deficiency heightened inflammation and altered AKT/IRS1 phosphorylation in 3T3-L1 cells.
  • GPR50 knockout suppressed PPAR-γ expression.

Conclusions:

  • GPR50 attenuates inflammation and regulates insulin signaling in adipocytes.
  • GPR50's effects are mediated via the IRS1/AKT pathway and PPAR-γ.
  • GPR50 shows potential as a therapeutic target for type 2 diabetes.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
386
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K